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Summary
 
We previously found that activation of primary CD4
 
1
 
 T cells via both the T cell antigen re-
ceptor (TCR) and CD28 is required for HIV-1 DNA to be translocated from the cytoplasm to
the nucleus. Here we report that expression of c-Myc protein in CD4
 
1
 
 T cells is induced only
after such costimulation. In addition, cyclosporin A not only inhibits nuclear import of HIV-1
DNA but also inhibits expression of c-Myc protein. Because of these correlations, we tested
whether c-Myc is necessary for nuclear import of HIV-1 DNA. Specific 
 
c-myc
 
 antisense, but
not sense or non-sense, phosphorothioate oligodeoxynucleotides selectively induced the accu-
mulation of two NH
 
2
 
-terminally truncated c-Myc proteins and abolished HIV-1 genome entry
into host nuclei. Consequently, both virus replication and HIV-1–induced apoptotic cell death
were inhibited. Synthesis of viral full-length DNA was not affected. Specific 
 
c-myc
 
 antisense oli-
gonucleotide inhibited HIV-1 infection under conditions that did not affect cell cycle entry or
proliferation. Thus, c-Myc appears to regulate HIV-1 DNA nuclear import via a mechanism
distinct from those controlling entry into the cell cycle.
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T
 
he life cycle of human immunodeficiency virus 1
(HIV-1) in infected cells can be divided into pre- and
postintegrated stages. After HIV-1 binds to the surface of T
cells through interaction of the envelope protein gp120
with CD4 and a seven-span transmembrane chemokine
receptor, the virus fuses with the host cell, enters the cyto-
plasm, and disassociates from the cell membrane (1–4). Vi-
ral reverse transcription is initiated, then linear double-
stranded viral DNA is synthesized, followed by formation
 
of virus preintegration complexes (PIC)
 
1
 
 (5). Double-stranded
viral DNA within these complexes migrates to the host nu-
cleus and integrates into the host cell genome, or forms cir-
cular molecules without the capacity to integrate (6, 7). After
a latency period, proviruses can be induced by a variety of
stimuli to replicate and this in turn can lead to depletion of
 
CD4
 
1
 
 T cells by a process of programmed cell death (8, 9).
Full-length HIV-1 DNA synthesis and translocation to
the nucleus are dependent upon activation of T cells (10–
16). Two T cell activation signals are required for the syn-
thesis and nuclear translocation of simian immunodefi-
ciency virus (SIV) or HIV-1 DNA (14, 17): one signal
through the TCR, which normally regulates the G0 to G1
transition, induces full-length viral DNA synthesis; the sec-
ond signal, through CD28 or the IL-2 receptor complex
(IL-2R), which regulates the G1 to S transition, controls
viral DNA entry into the nucleus. Furthermore, cyclo-
sporin A (CSA), a T cell activation inhibitor, and mi-
mosine, a late G1 phase inhibitor, abrogate nuclear import
of SIV or HIV-1 genomes (14, 17, 18). However, the cel-
lular factors involved in regulation of this process are not
well understood.
One candidate molecule regulated by lymphocyte acti-
vation is c-Myc, a transcription factor that has been impli-
cated in regulation of cell activation, differentiation, cell
cycle progress, transformation, and apoptosis (19–25). The
 
c-myc
 
 proto-oncogene is an immediate-early gene rapidly
induced during the G0 to G1 transition in activated T cells
(20–22). An IL-2R–dependent signaling pathway is re-
quired for induction of 
 
c-myc
 
 expression (26–30) and CSA
suppresses c-myc gene transcription (31). These observa-
tions suggested that c-Myc might play a key role in the
regulation of HIV-1 DNA nuclear import.
Here we present evidence that expression of c-Myc oc-
curs as a consequence of T cell costimulation. In addition,
blocking c-Myc by CSA correlates with this drug’s inhibi-
tory effect on translocation of HIV-1 genome to the nu-
cleus. Furthermore, specific 
 
c-myc
 
 antisense, but not corre-
sponding sense, non-sense, or scrambled phosphorothioate
oligodeoxynucleotides (PS-ODNs), selectively abolished
HIV-1 DNA entry into host nuclei and induced 46- and
50-kD truncated c-Myc proteins whose NH
 
2
 
-terminal
 
1
 
Abbreviations used in this paper:
 
 c-MycS, c-Myc short; CSA, cyclosporin
A; PS-ODN, phosphorothioate oligodeoxynucleotide; PIC, pre-integra-
tion complexes; TUNEL, TdT-mediated dUTP nick-end labeling. 
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transactivation domains are deleted. As a result, both replica-
tion and the cytopathic effects of HIV-1 were inhibited.
Specific 
 
c-myc
 
 antisense PS-ODNs inhibited HIV-1 infec-
tion without affecting cell cycle entry or proliferation, sug-
gesting that c-Myc regulates HIV-1 DNA nuclear import
via a mechanism distinct from those controlling entry into
the cell cycle.
 
Materials and Methods
 
Reagents.
 
PS-ODNs used in this study were synthesized by
Oligo Etc. Sequences used were as previously described (23): 
 
c-myc
 
antisense, AACGTTGAGGGGCAT, located in exon 2 of initia-
tion site of translation; sense 
 
c-myc
 
, ATGCCCCTCAACGTT;
non-sense, AGTGGCGGAGACTCT; and scrambled, AAGCA-
TACGGGGTGT containing a GGGG motif (32). The oligonu-
cleotides were dissolved in 30 mM Hepes (pH 7.0). Purified
mAbs to human CD8 (G10-1, IgG2a), CD16 (FC-2, IgG2b),
CD20 (1F5, IgG2a), and HLA-DR (HB10a, IgG2a) were pro-
duced in our lab and used to purify human primary CD4
 
1
 
 T cells
as previously described (14). Goat anti–mouse IgG conjugated
to magnetic microbeads was purchased from Miltenyi Biotec.
mAbs to human CD3 (64.1, IgG2a) and CD28 (9.3, IgG2a) were
used to activate CD4
 
1
 
 T cells as previously described (14).
Phospho–c-Myc (Thr58/Ser62) polyclonal antibody was pur-
chased from New England Biolabs. Anti–human c-Myc mAb
(9E10, IgG1), rabbit polyclonal antibody specific to NH
 
2
 
-termi-
nal region 1–262 amino acids of c-Myc (N-262), and rabbit poly-
clonal anti-ERK1 (c-16) antiserum were obtained from Santa
Cruz Biotechnology. PE-conjugated anti–HIV-1 p24 protein
mAb was purchased from Coulter Corp. TUNEL (TdT-medi-
ated dUTP nick-end labeling) detection kits were obtained from
Boehringer Mannheim.
 
CD4
 
1
 
 T Cell Isolation.
 
Enriched preparations of human CD4
 
1
 
T cells were isolated from peripheral blood samples from healthy,
HIV-seronegative donors as follows: PBLs were obtained by cen-
trifugation over Ficoll-Hypaque, and then E-rosette–positive (Er
 
1
 
)
cells were isolated as previously described (33). CD4
 
1
 
 T cells
were obtained by negative selection of Er
 
1
 
 cells depleting CD8
 
1
 
,
CD16
 
1
 
, CD20
 
1
 
, and HLA-DR
 
1
 
 cells with mAb-coated beads.
The purity of isolated CD4
 
1
 
 cells was 
 
.
 
97% as monitored by flow
cytometry. Cells were cultured in RPMI 1640 medium sup-
plemented with 10% heat-inactivated fetal bovine serum, 2 mM
glutamine, 10 U/ml penicillin, 10 mg/ml streptomycin, 1 mM py-
ruvate, and nonessential amino acids.
 
HIV-1 Infection.
 
HIV-1 strain Lai was prepared as previously
described (14). Cells were infected with HIV-1 at a multiplicity
of infection of 0.01 per cell.
 
PCR to Monitor Initiation and Elongation of HIV-1 DNA Synthe-
sis and Viral DNA Nuclear Import.
 
DNA was extracted from
HIV-1– and heat-inactivated HIV-1–infected cells as previously
described (14). PCR was performed as described (14) with some
modifications including: 50 ng of DNA/sample for amplification
of 
 
b
 
-globin, 100 ng for LTR/LTR products, 250 ng for LTR/
gag products, and 750 ng for LTR/circle products. PCR mix-
tures contained 1 
 
m
 
M of each primer, 200 
 
m
 
M each of the four
deoxynucleoside triphosphates, 1.5 mM MgCl
 
2
 
, 10 mM Tris-
HCl (pH 8.3), 50 mM KCl, and 0.2 U Tag DNA polymerase
(GIBCO BRL). The final volume was 50 
 
m
 
l. The reaction was
subjected to 32 cycles (30 cycles for 
 
b
 
-globin) of denaturation for
45 s at 94
 
8
 
C, annealing for 1 min at 60
 
8
 
C, and elongation for 2
min at 70
 
8
 
C. PCR products were subjected to 2% agarose gel
containing 0.01 
 
m
 
g/ml ethidium bromide and were visualized by
UV light. Primers used in this study have been described (14).
 
Western Blot Analysis.
 
After various treatments, 5 
 
3
 
 10
 
6
 
 pri-
mary CD4
 
1
 
 T cells were lysed in 500 
 
m
 
l lysis buffer (2% NP-40,
0.5% sodium deoxycholate, 0.2% SDS, 25 mM Tris-HCl, 50 mM
NaCl, 1 mM PMSF, 1 mM Na
 
3
 
VO
 
4
 
, 10 
 
m
 
M E-64 [trans-epoxy-
succinylt-
 
l
 
-leucylamido (4-guanidino)-butane], 1 
 
m
 
g/ml pepsta-
tin, 10 
 
m
 
g/ml leupeptin, and 0.1% aprotinin). After incubation
on ice for 30 min the cells were sonicated. The cell lysates
(equivalent to 10
 
6
 
 primary CD4
 
1
 
 T cells) were mixed with 2
 
3
 
SDS loading buffer (125 mM Tris-HCl [pH 6.8], 4% SDS, 20%
glycerol, 83 mM dithiothreitol, and 0.02% bromophenol blue),
incubated at 100
 
8
 
C for 5 min, electrophoresed by 8% SDS-poly-
acrylamide gel, and then transferred to nitrocellulose membranes
(Schreicher & Schuell). The membranes were blocked with 5%
nonfat milk-TBST (50 mM Tris-HCl [pH 7.4], 150 mM NaCl,
0.1% Tween 20) at 4
 
8
 
C overnight, followed by incubation with
primary antibodies (in 5% BSA-TBST) at 4
 
8
 
C overnight. After
washing, membranes were incubated with horseradish peroxi-
dase–conjugated second antibodies at room temperature for 1 h.
Bands on the blotted membranes were detected by incubation
with enhanced chemiluminescence reagent (ECL) (Amersham)
for 1 min and exposure to Kodak X-Omat film (Eastman-Kodak
Co.).
 
Flow Cytometry.
 
Apoptotic cell death followed by HIV-1 in-
fection was detected by TUNEL according to the manufacturer’s
protocol (Boehringer Mannheim). After TUNEL staining, cells
were resuspended in 100 
 
m
 
l PBS containing 1% BSA; PE-conju-
gated anti–HIV-1 p24 mAb was added and incubated at 4
 
8
 
C for
20 min. The cells were washed with cold PBS, suspended in 1%
paraformaldehyde (Sigma Chemical Co.), and kept at 4
 
8
 
C in the
dark until flow cytometry analysis by means of FACScan
 
®
 
 (Bec-
ton Dickinson). Cell cycle stages were determined by measuring
DNA content with propidium iodide as previously described (34).
 
Cell Proliferation.
 
Cell proliferation was estimated by [
 
3
 
H]thy-
midine incorporation: 10
 
5
 
 primary CD4
 
1
 
 T cells in the presence
or absence of oligodeoxynucleotides were stimulated with CD3
(10 
 
m
 
g/ml) and CD28 (20 
 
m
 
g/ml) mAbs in triplicate in 96-well
plates. The cells were incubated at 37
 
8
 
C in a 5% CO
 
2
 
 incubator
for 3 d. Each well was pulsed for 16 h with 0.5 
 
m
 
Ci [
 
3
 
H]thymi-
dine, and then the incorporation of [
 
3
 
H]thymidine radioactivity
was monitored by a beta counter.
 
Results and Discussion
 
In our previous study we found that HIV-1 nuclear im-
port required a CSA-sensitive pathway, and that both
TCR and CD28 ligation are essential for this process (14).
Similarly, the expression of c-Myc in primary CD4
 
1
 
 T
cells required costimulation with CD3 and CD28 mAbs
(Fig. 1 A); neither CD3 nor CD28 ligation alone induced
c-Myc expression. Time course experiments showed that
c-Myc expression increased by 4 h, peaked at 24 h after co-
stimulation, and was sustained for 48 h. Moreover, CSA
inhibited c-Myc expression (Fig. 1 A, bottom). Because of
this correlation, we tested whether c-Myc might be a key
regulator of HIV-1 DNA nuclear import in primary T
cells. Since no c-Myc–specific inhibitor is yet available, we
used a 
 
c-myc
 
 antisense PS-ODN to inhibit c-Myc function.
By competitively inhibiting HIV-1 reverse transcriptase
binding to the virus genome–cellular primer complex, PS- 
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ODNs have an inhibitory effect on the initiation of HIV-1
reverse transcription in a sequence-independent manner
(35, 36). However, sequence-independent PS-ODNs do
not exhibit any anti–HIV-1 activity once initiation of virus
reverse transcription has begun (35–38). To avoid nonspe-
cific anti-HIV activity of sequence-independent PS-ODNs,
we first infected activated CD4
 
1
 
 T cells with HIV-1 for 24 h
and then administrated graded doses of 
 
c-myc
 
 antisense, sense,
or non-sense PS-ODNs to the infected cells. As shown in
Fig. 1 B, initiation of reverse transcription (LTR/LTR
product) and full-length viral DNA synthesis (LTR/gag
product) were not affected by the 
 
c-myc
 
 antisense PS-ODN.
However, nuclear import of HIV-1 DNA (LTR circles)
was blocked by 
 
c-myc
 
 antisense PS-ODN even at doses as
low as 1 
 
m
 
M. Doses below to 0.2 
 
m
 
M were less efficient at
inhibiting LTR circle formation (data not shown). Neither
 
c-myc
 
 sense nor non-sense PS-ODN had any effect on viral
DNA nucleus translocation up to 8 
 
m
 
M (Fig. 1 B). Conse-
quently, HIV-1–infected cells treated with 
 
c-myc
 
 antisense
PS-ODN did not produce p24 gag protein or undergo
 
apoptosis (Fig. 1 C). Under conditions in which HIV-1 had
already entered the nucleus (e.g., at 48 h), 
 
c-myc
 
 antisense
PS-ODN did block viral p24 expression (data not shown).
Lack of an effect by 
 
c-myc
 
 antisense PS-ODN on full-length
viral DNA synthesis was not simply because the oligonu-
cleotides were added too late to the cultures (after 24 h in-
fection), as full-length viral DNA was not detectable until
at least 40 h after HIV infection in activated CD4
 
1
 
 T cells
(reference 14 and data not shown). Thus, 
 
c-myc
 
 antisense
PS-ODN apparently selectively acts on the stage of HIV-1
DNA nuclear import.
We next studied whether 
 
c-myc
 
 antisense PS-ODN spe-
cifically inhibited full-length c-Myc protein expression.
Using mAb 9E10 specific to the COOH-terminal end of
c-Myc (39), we consistently observed that in the presence
of 
 
c-myc
 
 antisense, sense, or non-sense PS-ODNs, the two
major forms of c-Myc proteins, p64 and p67, remained
relatively unchanged (Fig. 2). However, 
 
c-myc
 
 antisense
PS-ODN selectively induced the accumulation of 46- and
50-kD proteins, whose expression levels were higher than
Figure 1. A c-myc antisense PS-ODN, but not sense or non-sense PS-ODNs,
inhibits HIV-1 LTR circle formation in primary CD41 T cells. (A) Induction of
c-Myc expression by CD3 and CD28 costimulation in primary CD41 T cells is
shown in the top panel. CD41 T cells purified from human PBLs were stimu-
lated with 20 mg/ml of anti-CD28 (aCD28), 10 mg/ml of anti-CD3 (aCD3)
alone, or anti-CD3 plus anti-CD28 (aCD31aCD28), or were left unstimulated
(media) for the times indicated. c-Myc protein expression was evaluated by
Western blot analysis. The same blot was stripped and reprobed with ERK1 anti-
sera as a protein loading control. (Bottom panel) CSA inhibited c-Myc expression. Primary CD41 T cells were stimulated with CD3 and CD28 mAbs in
the presence or absence of CSA (1 mg/ml) for 24 h. Cell lysates were performed by Western blot analysis to detect c-Myc protein expression. Similar re-
sults were obtained in three additional experiments. (B) c-myc antisense, but not sense or non-sense, PS-ODN inhibits HIV-1 LTR circle formation in
primary CD41 T cells. Human peripheral blood CD41 T cells were stimulated with anti-CD3 mAb plus anti-CD28 mAbs and infected with HIV-1 at
the same time. After 24 h, cells were treated with graded doses of c-myc antisense, sense, or non-sense PS-ODNs or were left untreated. DNA was ex-
tracted at 3 d after infection, and levels of initiation of reverse transcription (LTR/LTR), full-length viral DNA synthesis (LTR/gag), and formation of
LTR circles were monitored by PCR. DNA from heat-inactivated HIV-1 (HI–HIV-1)–treated cells was run in parallel. Different amounts of DNA ex-
tracted from HIV-1–infected C8166 T cells were run as a positive control. One of three similar experiments is shown. (C) c-myc antisense PS-ODN in-
hibits HIV-1 replication and apoptosis of host T cells. Human CD41 T cells were infected with HIV-1, and PS-ODNs (1 mM) were added to the cul-
tures 24 h later and refreshed every 2 d. At day 6, intracellular double-staining with PE-conjugated anti-HIV p24 protein mAb and FITC-conjugated
TUNEL were performed to detect HIV-1 replication and induction of apoptosis. One of two representative experiments is shown.1394 Regulation of HIV-1 Infection by c-Myc
that of the full-length c-Myc. Neither the c-myc sense nor
non-sense PS-ODN induced accumulation of these two
proteins (Fig. 2, top). These data are consistent with previous
studies showing that expression of c-Myc short (c-MycS)
proteins in some tumor cell lines arised from two transla-
tional initiation sites downstream of the full-length c-Myc
start codon (40–45). These downstream-initiated c-MycS
proteins lack most of the NH2-terminal transactivation do-
main; they are produced through a leaky scanning mecha-
nism, since optimization of the traditional initiation codon
for full-length c-Myc results in less synthesis of the c-MycS
proteins (45). Because the c-myc antisense oligonucleotide
we used corresponds to the initiation site of full-length c-Myc
mRNA, and the two smaller proteins we detected are
about the same size as c-MycS isoforms, it seemed likely
that the 46- and 50-kD proteins are produced through the
same mechanism leading to deletion of the NH2-terminal
region. This possibility was substantiated by the fact that
antibodies specific to either NH2-terminal phosphorylated
Thr58/Ser62 or the whole NH2 terminus region of c-Myc
failed to recognize 46- and 50-kD proteins (Fig. 2, middle
and bottom). However, both antibodies were able to rec-
ognize p64 and p67 full-length c-Myc, which did not
change expression in cells treated with different PS-ODNs
(Fig. 2). The same result was obtained in a CD41 lymphoid
cell line, CEM (data not shown). Thus, the c-myc antisense
oligonucleotides, but not control PS-ODNs, selectively in-
duce NH2-terminally truncated c-Myc proteins that are
known to act as dominant negative inhibitors by competi-
tively suppressing full-length c-Myc functions (45–48).
Blockage of HIV-1 DNA nuclear import by c-myc antisense
Figure 2. c-myc antisense PS-
ODN induces accumulation of
46- and 50-kD NH2-terminally
truncated c-Myc proteins in anti-
CD3 and anti-CD28 activated
CD41 T cells. Human PBL
CD41 T cells were stimulated
with CD3 and CD28 mAbs for
24 h followed by incubation
with PS-ODNs for another 24 h
at indicated concentrations. c-Myc
proteins were detected by West-
ern blotting with 9E10 mAb
(top), or with an antibody specific
to phosphorylated Thr58/Ser62
of c-Myc (middle), or with an an-
tibody specific to the NH2-termi-
nal region of c-Myc, respectively
(bottom). The migration of mol
wt markers is indicated on the
left. Similar results were obtained
in three additional experiments.
Figure 3. c-myc antisense PS-ODN has no effect on cell cycle progres-
sion or proliferation of T cells under conditions of inhibition of HIV-1
infection. Human PBL CD41 T cells were stimulated with CD3 plus
CD28 mAbs for 24 h and then incubated with PS-ODNs or the cell cycle
inhibitor mimosine as indicated. (A) At day 4, cells were stained with
propidium iodide and DNA content was detected by flow cytometry.
The percentages of cells in each cell cycle phase were determined with
the use of MCycle plus software (Phoenix Flow Systems). (B) Cells were
pulsed with 0.5 mCi of [3H]thymidine for 16 h before harvesting at day 3
and incorporated [3H]thymidine was monitored by beta counter. One of
three representative experiments is shown.1395 Sun and Clark
PS-ODN most likely is mediated by these NH2-terminally
truncated c-Myc proteins. 
Finally, we tested whether c-myc antisense PS-ODN
could inhibit the entry of cell cycle and proliferation in-
duced in primary CD41 T cells after TCR and CD28 liga-
tion. Treating CD41 T cells with 6 mM of c-myc antisense
oligonucleotide, which efficiently blocked HIV-1 LTR
circle formation, could not inhibit cell cycle progression
(Fig. 3 A). Similarly, c-myc antisense, sense, and non-sense
PS-ODN had no effects on CD41 T cell proliferation in-
duced by CD3 plus CD28 mAbs (Fig. 3 B). These data are
consistent with previous findings that NH2-terminally
truncated c-Myc proteins do not interfere with cell growth
(45, 49).
The study presented here reveals a novel function of
c-Myc for regulation of HIV-1 nuclear import. Blocking of
HIV-1 DNA nuclear import by c-myc antisense PS-ODN
appeared to be mediated through the presence of 46- and
50-kD NH2-terminally truncated c-Myc proteins, which
do not affect cell cycle progression or cell proliferation (Fig.
3, A and B). Our data imply that the mechanism by which
c-Myc controls HIV-1 DNA nuclear import is distinct
from those controlling cell cycle progression. However,
precisely where and how c-Myc is required for HIV-1
DNA nuclear import in proliferating CD41 T cells remains
to be discovered. NH2-terminal–defective c-Myc proteins
are able to heterodimerize with Max, translocate to nu-
cleus, repress gene expression, stimulate cellular prolifera-
tion, and induce cell apoptosis (49). However, c-MycS
proteins are not able to activate gene transcription (49). It is
probable that c-Myc regulates HIV-1 DNA nuclear import
through its transactivation activity by regulation down-
stream gene expression. The ability of HIV-1 to infect
nondividing cells, such as monocytes, terminally differenti-
ated macrophages, mucosal dendritic cells, or g-irradiated
cells, is believed to be a unique feature since oncoretrovi-
ruses only can establish infection when the cells undergo
mitosis (50–57). The ability of HIV-1 to infect nondividing
cells is presumably related to the fact that its PIC can be
recognized by the cell nuclear import machinery (58–61)
and actively transported through nucleopores (62). More-
over, a cellular serine/threonine protein kinase, mitogen-
activated protein kinase (MAPK), can associate with HIV-1
PIC to facilitate nuclear targeting of viral DNA (63–66). It
is unclear whether HIV-1 DNA nuclear import in prolifer-
ating CD4 T cells is regulated through the identical path-
way seen in nondividing cells. A reasonable possibility is
that c-Myc affects the expression of genes encoding cellular
proteins involved in nuclear transport. Further elucidation
of the role of c-Myc in regulation of expression of cellular
nuclear importing molecules might help us to understand
how c-Myc regulates HIV-1 DNA nuclear import.
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